LB PHARMACEUTICALS INC (LBRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US50180M1080
LB PHARMACEUTICALS INC financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -29.12 m USD |
| Net income | -25.21 m USD |
| Diluted EPS – continuing operations | -3.13 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About LB PHARMACEUTICALS INC
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
More stocks
- Silicon2 Co. Ltd. (257720.KQ)
- Alpha Tau Medical Ltd (DRTS)
- FADU Inc. (440110.KQ)
- Metsa Board Oyj (METSB.HE)
- AcadeMedia AB (ACAD.ST)
- Domino's Pizza Group PLC (DOM.L)
- Emperador Properties SOCIMI SA (YEPSA.MC)
- Patria Private Equity Trust PLC (PPET.L)
- Orezone Gold Corp (ORE.TO)
- Piedmont Realty Trust, Inc. (PDM)
- LendLease Group (LLC.AX)
- Piraeus Port Authority SA (PPA.AT)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.